Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.

@article{Mcauley2017KeratinocyteGF,
  title={Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.},
  author={D F Mcauley and L J Mark Cross and Umar Imran Hamid and Evie Gardner and J Stuart Elborn and Kathy M Cullen and Ahilanandan Dushianthan and Michael P. W. Grocott and Michael A. Matthay and Cecilia O'kane},
  journal={The Lancet. Respiratory medicine},
  year={2017},
  volume={5 6},
  pages={484-491}
}
BACKGROUND Data from in-vitro, animal, and human lung injury models suggest that keratinocyte growth factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS). The objective of this trial was to investigate the effect of KGF in patients with ARDS. METHODS We did a double-blind, allocation concealed, randomised, placebo-controlled phase 2 trial in two intensive care units in the UK, involving patients fulfilling the American-European Consensus Conference Definition of ARDS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…